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OBJECTIVE: To determine the rate of CVD in asymptomatic
individuals with diabetes mellitus [DM] using non-invasive
myocardial perfusion imaging [MPI]. METHODS: This obser-
vational study identiﬁed individuals with DM [ICD-9-CM
250.0] from an administrative database maintained by VISN 22
[Department of Veterans’ Affairs]; and, patients received all in-
patient and out-patient care from this VISN. One cohort of 53-
year old males consisted of individuals who did not undergo MPI
over a 24-month interval [n = 60]; another cohort included
attribute-matched individuals who had undergone MPI during
the same interval. This group did not undergo MPI due to
ischemia or other clinical ﬁndings of CAD. Evidence of MPI uti-
lization consisted of HCPCS code assignment. Patient records
were examined to identify post-MPI CVD and interval morbid-
ity. RESULTS: Of those who did not undergo MPI, 15% expe-
rienced CVD-related events during the observation interval
including acute MI [n = 7], dysrhythmias, and heart failure;
however, 25% of MPI studies were abnormal in the second
cohort, no patients experienced acute MI, and dysrhythmias and
heart failure occurred in two patients [p < 0.01]. The rate of
CVD events in the ﬁrst cohort is 0.375/month whereas in the
second cohort it is 0.083/month [p < 0.001]. Half of the abnor-
mal MPI studies identiﬁed multi-vessel CAD. Eleven patients
underwent CABG procedures in the second cohort based on ﬁnd-
ings at MPI; none of the non-MPI patients underwent such inter-
vention. CONCLUSIONS: MPI detected CVD in asymptomatic
patients with DM which resulted in appropriate intervention and
improvement in net health outcomes. Up to 22% of individuals
in the US with DM have asymptomatic CVD, and appropriate
use of MPI should be considered in this setting.
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OBJECTIVE: To compare African-American patients (16% of
the population) and Latino patients (15% of the population) to
their respective complementary cohorts of all other patients
(including 66% Caucasian, and 3% others) in terms of glycemic
response to pioglitazone combination therapy. METHOD:
Twenty-four-week data from three randomized controlled trials,
each using 30- or 45mg doses of pioglitazone combined with i)
sulfonylurea; ii) metformin; or iii) insulin for 24-weeks, were
analyzed. Mean changes from baseline in hemoglobin A1c
between (a) African-Americans and all others and (b) Latinos
and all others were compared using regression models with base-
line demographics and hemoglobin A1c as covariates. RESULTS:
Baseline hemoglobin A1c measurements ranged from 10.11 to
10.86 among African-Americans, from 9.73 to 10.11 among
Latinos, and from 9.57 to 9.89 among all others. The mean
reduction in hemoglobin A1c from baseline was statistically sig-
niﬁcant in every African-American treatment group (-0.96% to
-2.34%) and every Latino treatment group (-1.26% to -1.85%)
as well as the “all others” groups. Signiﬁcantly larger mean
reductions in hemoglobin A1c were detected in African-
Americans than all others in two treatment groups (receiving
higher doses of pioglitazone with sulfonylurea and with met-
formin) and in Latinos in one treatment group (the lower dose
of pioglitazone with metformin combination). Patients with rel-
atively higher baseline hemoglobin A1c and body mass index
measurements tended to beneﬁt more from treatment. CON-
CLUSION: Data from three clinical trials show that African-
Americans and Latinos attained decreases in hemoglobin A1c
levels using pioglitazone combination therapy. Generally, the
improvements in hemoglobin A1c in African-Americans and
Latinos were comparable to the corresponding cohorts of all
others.
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OBJECTIVES: Diabetic patients have increased risk of develop-
ing Alzheimer’s disease (AD). Recent clinical studies have shown
that the use of insulin-response enhancers, (rosiglitazone and
pioglitazone), have improved memory functioning in patients
with mild Alzheimer’s disease. We hypothesized that the use of
glitazones may reduce the risk of AD in diabetic patients.
METHODS: Diabetic patients were identiﬁed from a 20%
sample of California Medicaid claims database from 1995–2002.
Diabetic patients were divided into a glitazone group and a rel-
atively comparable control group that had at least an interclass
switching or combination regimen. Index events were the ﬁrst
glitazone prescription for the experimental group, or the ﬁrst
switching or combination regimen for the control group. Six
months of continuous eligibility were required prior to the index
event, and patients were followed until admission to nursing
home, disenrollment or the end of study period. Patients with
any diagnosis of AD prior to index event were excluded. We used
Cox proportional hazard model to adjust for variable length of
follow-up periods and account for censoring. RESULTS: In total,
16,378 patients in glitazone group and 7313 controls met selec-
tion criteria. Glitazone patients were older (64.1 vs. 54.3 years,
p < 0.0001), had signiﬁcantly higher incidence of each of four-
teen morbidities included (diabetic complications, dementia,
depression, hypertension, CHF, CHD, etc.), and more resource
utilization than control group. However, glitazone patients had
fewer incidence of AD during the follow-up period than the
control group (0.33% vs. 0.62%, p = 0.0016). After controlling
for risk factors, use of glitazone was associated with 55% risk
reduction of developing AD (HR = 0.448, p = 0.01). Additional
analysis revealed no signiﬁcant difference between rosiglitazone
and pioglitazone in risk reduction. CONCLUSIONS: Use of gli-
tazones signiﬁcantly reduced the risk of AD in the study popu-
lation.This implied a preventive utility of glitazones in delaying
the onset of AD in diabetic population.
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OBJECTIVE: The goal of this study is to evaluate treatment pat-
terns in the management of type-2 diabetes (T2D) patients, with
coexisting comorbidities, including cardiovascular diseases and
hyperlipidemia. METHODS: In a retrospective cohort study cov-
ering three 12-month periods (2001, 2002 and 2003), we ana-
lyzed the treatment of newly diagnosed T2D patients. We kept
track of records for each cohort in the subsequent 12-months
after the initial diagnosis. The study was based on the analysis
of electronic CMS1500 medical claims for more than 2,466,131
unique patients (HIPAA compliant). The patients’ medication
records were assessed through NCPDP electronic pharmacy
claims utilizing NDC codes and drug classes. RESULTS: Between
2000 and 2003, only 30.8%–35.8% of all patient cohorts did
not have comorbidities. The highest level of comorbidities preva-
lence was discovered within older patients. In 2003, the per-
